Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Most patients with appendicitis can have antibiotics as their first treatment, rather than appendectomy

But researchers of U.S. "CODA" trial find that some patients eventually need the operation


News provided by

American College of Surgeons

Oct 25, 2021, 11:00 ET

Share this article

Share toX

Share this article

Share toX

CHICAGO, Oct. 25, 2021 /PRNewswire/ --

Key takeaways

Continue Reading
Researchers of the U.S. "CODA" trial find that most patients with appendicitis can have antibiotics as their first treatment, rather than appendectomy, but some patients eventually need the operation. David R. Flum, MD, MPH, FACS, and Giana H. Davidson, MD, MPH, FACS from the University of Washington School of Medicine explain the findings published in The New England Journal of Medicine and presented simultaneously at the American College of Surgeons virtual Clinical Congress 2021.
Researchers of the U.S. "CODA" trial find that most patients with appendicitis can have antibiotics as their first treatment, rather than appendectomy, but some patients eventually need the operation. David R. Flum, MD, MPH, FACS, and Giana H. Davidson, MD, MPH, FACS from the University of Washington School of Medicine explain the findings published in The New England Journal of Medicine and presented simultaneously at the American College of Surgeons virtual Clinical Congress 2021.

  • Study results show the safety and sustainability of another treatment option besides surgical removal of the appendix.
  • Study findings highlight the need for increased shared decision making between surgeons and patients on the need for and timing of an appendectomy.
  • To help patients make treatment decisions regarding their appendicitis, CODA investigators developed an online decision-making tool.

About half of patients with appendicitis do not need an appendectomy procedure up to four years after receiving a course of antibiotics, according to final results of the Comparison of Outcomes of antibiotic Drugs and Appendectomy (CODA) trial. The study findings were presented today at the American College of Surgeons (ACS) virtual Clinical Congress 2021, simultaneous with online publication in the New England Journal of Medicine.1

These results show the safety and sustainability of another treatment option besides surgical removal of the appendix. Appendectomy has been the standard appendicitis treatment for more than 120 years and is the most common emergency abdominal procedure in the U.S.2

The research findings also highlight the need for shared decision making between patients and surgeons, study investigators said.

"Based on their characteristics, circumstances, and priorities, antibiotics will be a good treatment for some, but probably not all patients with appendicitis," said co-principal investigator David R. Flum, MD, MPH, FACS, professor and associate chair of surgery at University of Washington (UW) School of Medicine in Seattle. David Talan, MD, emergency medicine physician, Geffen School of Medicine at UCLA, is also co-principal investigator.

CODA is the largest randomized clinical trial to explore whether antibiotic treatment is as good as appendectomy in treating appendicitis. The study was conducted at 25 U.S. medical centers in 1,552 adults with appendicitis who were randomly assigned to receive either antibiotics or appendectomy.

Based partly on early CODA results3 and evidence from other studies, the ACS strengthened its guidance for appendicitis treatment during the COVID-19 pandemic last December.4 The College called antibiotics "an acceptable first-line treatment" for most patients with appendicitis.

Higher need for appendectomy with time
Among the study patients who initially received nonoperative treatment, the proportion who eventually underwent an appendectomy increased over time. Preliminary results of the study, reported October 5, 2020, showed only 30 percent of the antibiotics-alone group required an appendectomy within three months.3 Recurrent appendicitis was the primary reason for getting an appendectomy after antibiotic treatment, according to updated results.

With longer-term follow-up, the investigators found appendectomy rates in the antibiotics group were 40 percent one year after antibiotic therapy and 46 percent at two years, rising to 49 percent at three and four years.

"While some clinicians and patients may determine that these longer-term rates of appendectomy make antibiotics a less desirable treatment, a very high proportion of patients report a preference for antibiotics, even if appendectomy may ultimately be necessary," the study authors wrote. They referred to recent survey results indicating patient preference.5

"Especially in the emergency setting, patients may prefer to avoid or delay an operation for reasons including current demands at work and home, lack of health insurance, or anxiety," said Giana H. Davidson, MD, MPH, FACS, a co-investigator and an associate professor of surgery at UW School of Medicine.

Complications were uncommon in both treatment groups after the first month, researchers reported. A predictor of antibiotic-treated patients eventually having an appendectomy was the presence in the first 48 hours of an appendicolith, or a small stone in the appendix. After 30 days, that increased risk reportedly decreased.

Decision-making help
To help patients make treatment decisions regarding their appendicitis, CODA investigators developed an online decision-making tool, available at http://www.appyornot.org/ (.) The decision aid includes a video in English and Spanish and provides information about treatment risks and benefits. It also asks users questions about personal preferences, priorities, and resources to help them choose a treatment based on their individual situation.

"Our hope is that a standardized tool that can be easily disseminated across health systems can help patients effectively get information about their diagnosis and clinical outcomes, and help facilitate treatment discussions between patients and their surgeons," Dr. Davidson said. "It has input from patient stakeholders, surgeons, and emergency medicine doctors to help give patients the information they need to make their choices."

The online tool will be part of a national implementation program, led partly by the ACS, which will include training clinicians and developing a protocol to standardize appendicitis treatment.

No single patient factor can predict the success or failure of either antibiotic or surgical treatment for every patient, said co-investigator Callie Thompson, MD, FACS, assistant professor of surgery, University of Utah Health, Salt Lake City.

"Picking 'the best' candidate for either therapy comes down to having a discussion with each patient about their goals and values for treatment of their appendicitis and discussing the risks and benefits of each treatment with those goals and values in mind," she said.

The CODA trial showed a higher long-term appendectomy rate in antibiotic-assigned patients than in a large similar study conducted in Europe ("APPAC" trial),6 which had a five-year appendectomy rate of 39 percent in its antibiotics group. The CODA trial differed, however, because it included patients with perforation of the appendix or an appendicolith, said co-investigator Lillian Kao, MD, MS, FACS, professor and division chief of acute care surgery at McGovern Medical School at UTHealth, Houston.

Although the CODA trial did not include children, Dr. Davidson said other studies are ongoing in pediatric patients with appendicitis to determine if initial treatment with antibiotics is right for them.

For a listing of CODA study sites and other study authors, click here (.)

"FACS" designates that a surgeon is a Fellow of the American College of Surgeons.

The CODA trial is funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (1409-24099).

The authors report no relevant disclosures.

Citation: CODA Collaborative. Antibiotics vs Appendectomy for Acute Appendicitis—Longer Term Outcomes. Research letter. N Engl J Med. 2021. DOI:10.1056/NEJMc2116018

Presented simultaneously at virtual American College of Surgeons Clinical Congress 2021.

1CODA Collaborative. Antibiotics versus Appendectomy for Acute Appendicitis—Longer Term Outcomes. Research letter. N Engl J Med. Posted online October 25, 2021. https://www.nejm.org (.)
2Newhall K, Albright B, Tosteson A, Ozanne E, Trus T, Goodney PP. Cost-effectiveness of prophylactic appendectomy: a Markov model. Surg Endosc. 2017 Sep;31(9):3596-3604.
3CODA Collaborative. A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis (CODA). N Engl J Med. 2020;383(20):1907-1919. DOI:10.1056/NEJMoa2014320 (.)4American College of Surgeons. ACS Strengthens Its Emergency General Surgery Guidelines for Appendicitis Treatment During COVID-19. Bulletin Brief. Posted online December 8, 2020. Accessed October 19, 2021. http://www.facs.org/publications/bulletin-brief/120820/clinical (.)5Rosen JE, Agrawal N, Flum Dr, Liao JM. Willingness To Undergo Antibiotic Treatment Of Acute Appendicitis Based on Risk of Treatment Failure. Letter. Br J Surg. Published online August 17, 2021. DOI:10.1093/bjs/znab280 (.)
6Salminen P, Paajanen H, Rautio T, et al. Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis: The APPAC Randomized Clinical Trial. JAMA. 2015;313(23):2340-2348.

About the American College of Surgeons
The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 84,000 members and is the largest organization of surgeons in the world. For more information, visit www.facs.org (.)

SOURCE American College of Surgeons

Related Links

https://www.facs.org/

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Surgeons: Obesity Isn't About Willpower -- It's a Treatable Medical Condition

Surgeons: Obesity Isn't About Willpower -- It's a Treatable Medical Condition

Obesity is a growing national health crisis, with nearly 40% of U.S. adults affected and about 10% having a severe form of the disease. Although...

The American College of Surgeons Advances New Clinical Data Strategy to Improve Surgical Care for Patients

Long recognized as a leader in the use of rigorously collected clinical data to improve surgical patient care, the American College of Surgeons (ACS) ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

Not For Profit

Not For Profit

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.